Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 50 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Intrathecal Double Checkpoint InhibitionActive, not recruitingNCT05598853Phase 1
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCActive, not recruitingNCT05595460Phase 1
- Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to SurgeryActive, not recruitingNCT05594290Phase 2
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Phase 3
- Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II StudyActive, not recruitingNCT05586100Phase 2
- First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Phase 2
- CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal CancerActive, not recruitingNCT05585814Phase 2
- Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Phase 2
- A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2
- Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRCTerminatedNCT05584137Phase 2
- A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ TrastuzumabStatus unknownNCT05583383Not applicable
- HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCCStatus unknownNCT05582278Phase 2
- AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)Status unknownNCT05578430Phase 2
- Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDStatus unknownNCT05578222Phase 2
- A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal CarcinomaActive, not recruitingNCT05576272Phase 2/3
- Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline TherapyWithdrawnNCT05574504Phase 2
- A Study of Radiation Therapy and Cemiplimab for People With Skin CancerActive, not recruitingNCT05574101Phase 2
- A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaWithdrawnNCT05572463Phase 1/2
- A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyCompletedNCT05568095Phase 3
- CISH Inactivated TILs in the Treatment of NSCLCWithdrawnNCT05566223Phase 1/2
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingNCT05565378Phase 2
- Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder CancerStatus unknownNCT05564897Phase 2
- Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular CarcinomaWithdrawnNCT05564338Phase 3
- TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedNCT05563480Phase 2
- Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Active, not recruitingNCT05563467Phase 2
- A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male SubjectsCompletedNCT05559554Phase 1
- Study of AK119 Combined With AK104 in Patients With Advanced Solid TumorsTerminatedNCT05559541Phase 1/2
- Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive, not recruitingNCT05557838Phase 3
- A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)Active, not recruitingNCT05557591Phase 2
- A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical CancerStatus unknownNCT05557565Phase 2
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell LungActive, not recruitingNCT05553834Phase 2
- Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT05552651Phase 2
- Induction Immunochemotherapy in Stage III-IVa Head and Neck CancerStatus unknownNCT05551767Phase 2
- Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal CancerStatus unknownNCT05551247Phase 2
- Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCCompletedNCT05549037Phase 3
- Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 ResectionActive, not recruitingNCT05546619Not applicable
- Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2
- Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of RecurrenceStatus unknownNCT05545124Phase 2
- Pembrolizumab Plus CRT Followed by Surgery in Upper ESCCStatus unknownNCT05541445Phase 1/2
- Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast CancerWithdrawnNCT05539365Phase 2
- BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell LymphomaWithdrawnNCT05538988Phase 1/2
- A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1
- Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerCompletedNCT05535569Phase 1/2
- Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung CancerStatus unknownNCT05529355Phase 2
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedNCT05529316Phase 2
- Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaActive, not recruitingNCT05524935Phase 2
- SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05524168Phase 2
- Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver MetastasisStatus unknownNCT05524155Phase 2
- AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCCStatus unknownNCT05522894Phase 2
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedNCT05522231Phase 2/3
- PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II TrialActive, not recruitingNCT05520814Phase 2
- Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)Active, not recruitingNCT05520619Phase 2
- Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric CancerStatus unknownNCT05519202Phase 2
- Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)WithdrawnNCT05518032Phase 2
- Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell CarcinomaCompletedNCT05517330Phase 2
- A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant TumorsCompletedNCT05516914Phase 1/2
- Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCCCompletedNCT05516589Phase 2
- Atezolizumab for Idiopathic Pulmonary FibrosisActive, not recruitingNCT05515627Phase 1
- Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialActive, not recruitingNCT05514990Phase 1/2
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingNCT05514132Phase 1
- Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
- Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05509699Phase 2
- Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2
- Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric CancerActive, not recruitingNCT05508737Phase 1/2
- Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid TumorsCompletedNCT05508100Phase 1
- TIME in Immunotherapy Combined With nCRT for Rectal CancerActive, not recruitingNCT05507112Phase 2
- A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerCompletedNCT05505825Phase 1/2
- Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaCompletedNCT05504720Phase 2
- Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05502315Phase 2
- Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete RemissionActive, not recruitingNCT05502250Phase 2
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05502237Phase 3
- PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant AscitesStatus unknownNCT05501340Phase 1/2
- Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingNCT05501054Phase 1/2
- AK112 in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT05499390Phase 3
- Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsCompletedNCT05498480Phase 1
- A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnNCT05496192Phase 2
- Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid TumorsTerminatedNCT05494762Phase 1
- A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.CompletedNCT05493995Phase 2
- Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.WithdrawnNCT05493618Phase 1/2
- HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCCStatus unknownNCT05493332Phase 2
- To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast CancerStatus unknownNCT05491694Phase 2
- Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 StudyActive, not recruitingNCT05491616Phase 2
- A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin LymphomasTerminatedNCT05490043Phase 1
- Immunotherapy Combined With Radiotherapy for Metastatic SarcomaActive, not recruitingNCT05488366Early Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT05487235Phase 1
- Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2
- A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)Active, not recruitingNCT05485753Phase 1/2
- Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05485350Phase 2
- Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant GliomaActive, not recruitingNCT05484622Phase 1
- Evaluating Novel Therapies in ctDNA Positive GI CancersActive, not recruitingNCT05482516Phase 3
- Nivolumab and All-trans Retinoic Acid for Pancreatic CancerStatus unknownNCT05482451Early Phase 1
- Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT05481476Phase 2
- Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionActive, not recruitingNCT05480384Phase 2
- A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer PatientsWithdrawnNCT05479045Phase 2
- Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05476380Phase 2
- Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabWithdrawnNCT05472623Phase 2
- Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck CancerWithdrawnNCT05472506Phase 1
- Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung CancerStatus unknownNCT05472467Phase 2
- Neoadjuvant Anti-PD1 in HCCCompletedNCT05471674Phase 2
- A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the LungActive, not recruitingNCT05470595Phase 2